The Cell Culture World Congress began in Munich in 2009, to help pharma and biotech companies using bioprocess to create their biologic drugs. The aim of the Congress was to provide a technical forum for cell culture and biomanufacture professionals through cutting edge commentary, case studies and real time practical application that would allow them to advance their own biopharmaceutical development, bioprocessing and manufacturing strategies.

After 6 years of growth and development, it has become the region’s premier Congress for the bioprocess industry. Addressing issues in cost, cell line, media, process development exploring new methods and technologies the congress quickly became the place where all major existing and emerging executives obtain practical and technical solutions to biomanufacturing.

The Congress is now a networking forum where pharma, biotech and academia wanting to progress within the cell culture and biomanufacturing market come together to exchange ideas.

2016 heralds a move to a new venue in the heart of Munich, with twice as many pharma and biotech attendees as 2015 and including Munich’s major biotech clusters this year’s conference is set to be better than ever. The Cell Culture World Congress 2016 will introduce new and exciting content focusing on innovation and commercialisation with an emphasis on new methods. Showcasing exciting new technologies such as CRISPR gene editing, 3D printing of bioreactors and new methods of vaccine production . Content will include cutting edge research and even more case studies, over 40 presentations from those working in bioprocess in big pharma, interactive sessions with biotechs and will be again co-located with the Downstream Processing
World Congress.

From process optimisation to commercial expansion and partnering, Cell Culture World Congress proudly welcomes 500 members of the bioprocess community to meet and do business in 2016.